Musculoskeletal Cancers Remote Monitoring and Care (NCT07129226)
🩺 Plain-English Summary (8th-Grade Level)
This study aims to evaluate how walking stability and the ability to perform daily activities change during cancer treatment, and whether a smartwatch can detect these changes. The goal is to develop proactive, personalized tools that automatically monitor treatment response and predict potential complications. To support future implementation, the study will assess the feasibility of wearing a smartwatch for at least 12 hours per day, using a mobile application, and completing weekly questionnaires among patients with primary osteosarcoma or metastatic bone disease.
Who can join: Review the eligibility criteria below.
Location: Case Comprehensive Cancer Center, Cleveland Clinic Foundation — Cleveland, Ohio
Age range: 18 Years
🧪 Interventions in This Study
- Smart Watch (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation — Cleveland, Ohio
📞 Contact the Study Coordinator
Phone: (216) 445-9174
Email: burkez@ccf.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Osteosarcoma
- Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors — New York, New York
- SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma — Los Angeles, California
- Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma — Birmingham, Alabama
- Olaparib With Ceralasertib in Recurrent Osteosarcoma — San Francisco, California
- A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma — Seattle, Washington
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma — Houston, Texas
Explore by condition: All Osteosarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.